Janssen Collaborates with Premier Inc. on Unique Study to Improve Stroke Risk Management among Hospitalized Patients with Atrial Fibrillation Last Updated: April 3, 2017
Filed under:
Print Friendly, PDF & Email

PR NewsWire: Janssen Pharmaceuticals, Inc. today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address an unmet medical need for hospitalized patients with atrial fibrillation (AF) who are at risk for ischemic stroke. Named QUANTUM AF (Quantify Use of ANTicoagUlation to improve Management of AF), the study will evaluate the effect of a structured hospital quality improvement (QI) program on oral anticoagulant (OAC) use in these patients.

Full story